Related references
Note: Only part of the references are listed.The Mechanisms of Differential Sensitivity to an Insulin-like Growth Factor-1 Receptor Inhibitor (BMS-536924) and Rationale for Combining with EGFR/HER2 Inhibitors
Fei Huang et al.
CANCER RESEARCH (2009)
Gastrosplenic Fistula From Hodgkin's Lymphoma
Carolyn D. Seib et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
被撤回的出版物: Phase II Study of the Anti-Insulin-Like Growth Factor Type 1 Receptor Antibody CP-751,871 in Combination With Paclitaxel and Carboplatin in Previously Untreated, Locally Advanced, or Metastatic Non-Small-Cell Lung Cancer (Retracted article. See vol. 30, pg. 4179, 2012)
Daniel D. Karp et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Insulin, the Insulin-Like Growth Factor Axis, and Mortality in Patients With Nonmetastatic Colorectal Cancer
Brian M. Wolpin et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Igf1r as a therapeutic target in a mouse model of basal-like breast cancer
Apostolos Klinakis et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Insulin Receptor Expression by Human Prostate Cancers
Michael E. Cox et al.
PROSTATE (2009)
Development of monoclonal antibodies for the treatment of colorectal cancer
Susan Goodin
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2008)
Feedback Mechanisms Promote Cooperativity for Small Molecule Inhibitors of Epidermal and Insulin-Like Growth Factor Receptors
Elizabeth Buck et al.
CANCER RESEARCH (2008)
Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody
Liang Cao et al.
CANCER RESEARCH (2008)
Phosphorylated Insulin-Like Growth Factor-I/Insulin Receptor Is Present in All Breast Cancer Subtypes and Is Related to Poor Survival
Jennifer H. Law et al.
CANCER RESEARCH (2008)
The Type 1 Insulin-Like Growth Factor Receptor Pathway
Meenali M. Chitnis et al.
CLINICAL CANCER RESEARCH (2008)
Targeting insulin and insulin-like growth factor signalling in oncology
Michael Pollak
CURRENT OPINION IN PHARMACOLOGY (2008)
Targeting the type 1 insulin-like growth factor receptor as a treatment for cancer
John S. P. Yuen et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2008)
Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 receptor monoclonal antibody CP-751,871 in patients with multiple myeloma
Martha Q. Lacy et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Targeting Polo-Like Kinase: Learning Too Little Too Late?
David Olmos et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase I and Pharmacokinetic Study of YM155, a Small-Molecule Inhibitor of Survivin
Anthony W. Tolcher et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
IGF-1 Receptor Inhibitors in Clinical Trials-Early Lessons
S. John Weroha et al.
JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA (2008)
Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: Lessons from the first clinical trials
Jordi Rodon et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis
Jing Ma et al.
LANCET ONCOLOGY (2008)
Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors
Chi Tarn et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Insulin and insulin-like growth factor signalling in neoplasia
Michael Pollak
NATURE REVIEWS CANCER (2008)
Integrated profiling of basal and luminal breast cancers
Jose Adelaide et al.
CANCER RESEARCH (2007)
An antibody targeting the type I insulin-like growth factor receptor enhances the castration-induced response in androgen-dependent prostate cancer
Stephen R. Plymate et al.
CLINICAL CANCER RESEARCH (2007)
Mechanisms of disease: signaling of the insulin-like growth factor I receptor pathway-therapeutic perspectives in cancer
Yungan Tao et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2007)
Phase I dose escalation study of the anti-insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors
Paul Haluska et al.
CLINICAL CANCER RESEARCH (2007)
Quantitative mass spectrometry identifies insulin signaling targets in C-elegans
Meng-Qiu Dong et al.
SCIENCE (2007)
A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor-dependent tumor growth in vivo
Qun-Sheng Ji et al.
MOLECULAR CANCER THERAPEUTICS (2007)
A phase I pharmacokinetic and pharmacodynamic study of AMG 479, a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R), in advanced solid tumors
A. W. Tolcher et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor
Johann S. de Bono et al.
CLINICAL CANCER RESEARCH (2007)
Growth hormone regulation of p85α expression and phosphoinositide 3-kinase activity in adipose tissue -: Mechanism for growth hormone-mediated insulin resistance
Juan-Pablo del Rincon et al.
DIABETES (2007)
Characterization of insulin/IGF hybrid receptors: contributions of the insulin receptor L2 and Fn1 domains and the alternatively spliced exon 11 sequence to ligand binding and receptor activation
Samira Benyoucef et al.
BIOCHEMICAL JOURNAL (2007)
Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1
Anthony W. Tolcher et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism
X. Wan et al.
ONCOGENE (2007)
The role of the IGF system in cancer growth and metastasis: Overview and recent insights
Amir Abbas Samani et al.
ENDOCRINE REVIEWS (2007)
Insulin-like growth factor-I receptor signaling blockade combined with radiation
Gregory W. Allen et al.
CANCER RESEARCH (2007)
The role of insulin receptor isoforms and hybrid Insulin/IGF-I receptors in human cancer
Antonino Belfiore
CURRENT PHARMACEUTICAL DESIGN (2007)
The insulin-like growth factor 1 receptor in cancer: Old focus, new future
Hermien Hartog et al.
EUROPEAN JOURNAL OF CANCER (2007)
Disrupting insulin-like growth factor signaling as a potential cancer therapy
Deepali Sachdev et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Down-regulation of type I insulin-like growth factor receptor increases sensitivity of breast cancer cells to insulin
Hua Zhang et al.
CANCER RESEARCH (2007)
Blastemal expression of type I insulin-like growth factor receptor in Wilms' tumors is driven by increased copy number and correlates with relapse
Rachael Natrajan et al.
CANCER RESEARCH (2006)
Caveolin-1 up-regulates IGF-1 receptor gene transcription in breast cancer cells via Sp1-and p53-dependent pathways
Chen Glait et al.
EXPERIMENTAL CELL RESEARCH (2006)
Combined in vivo effect of A12, a type 1 insulin-like growth factor receptor antibody, and docetaxel against prostate cancer tumors
Jennifer D. Wu et al.
CLINICAL CANCER RESEARCH (2006)
Epidermal growth factor receptor targeting in cancer
John Mendelsohn et al.
SEMINARS IN ONCOLOGY (2006)
The insulin-like growth factor I receptor is required for Akt activation and suppression of anoikis in cells transformed by the ETV6-NTRK3 chimeric tyrosine kinase
MJ Martin et al.
MOLECULAR AND CELLULAR BIOLOGY (2006)
Targeting insulin-like growth factor pathways
D Yee
BRITISH JOURNAL OF CANCER (2006)
Down-regulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: Implications for anti-insulin-like growth factor therapy in breast cancer
D Sachdev et al.
CANCER RESEARCH (2006)
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
KE O'Reilly et al.
CANCER RESEARCH (2006)
The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin
RJ Shaw et al.
SCIENCE (2005)
The insulin-like growth factor system and its pleiotropic functions in brain
VC Russo et al.
ENDOCRINE REVIEWS (2005)
A germ line mutation that delays prostate cancer progression and prolongs survival in a murine prostate cancer model
N Majeed et al.
ONCOGENE (2005)
Insulin-like growth factor-I, IGF-binding protein-3, and mammographic breast density
C Diorio et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2005)
In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors
JD Wu et al.
CLINICAL CANCER RESEARCH (2005)
Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871
BD Cohen et al.
CLINICAL CANCER RESEARCH (2005)
Insulin-like growth factors and neoplasia
MN Pollak et al.
NATURE REVIEWS CANCER (2004)
Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth
A Girnita et al.
CANCER RESEARCH (2004)
Growth patterns and the risk of breast cancer in women
M Ahlgren et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
The igf-1 receptor in cancer biology
R Baserga et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
Growth hormone receptor antagonists: Discovery, development, and use in patients with acromegaly
JJ Kopchick et al.
ENDOCRINE REVIEWS (2002)
Mechanisms of steroid impairment of growth
Z Hochberg
HORMONE RESEARCH (2002)
Fasting insulin and outcome in early-stage breast cancer: Results of a prospective cohort study
PJ Goodwin et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin)
YH Lu et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2001)
Reduced mammary gland carcinogenesis in transgenic mice expressing a growth hormone antagonist
M Pollak et al.
BRITISH JOURNAL OF CANCER (2001)
Growth hormone receptor is expressed in human breast cancer
M Gebre-Medhin et al.
AMERICAN JOURNAL OF PATHOLOGY (2001)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
